ARTICLE | Company News
SCM Lifescience, Yozma in MOU to develop stem cell therapies
August 3, 2018 5:44 PM UTC
SCM Lifescience (Incheon, South Korea) and Yozma Bio Science Holdings (Seoul, South Korea) signed a memorandum of understanding (MOU) on July 11 to co-develop next-generation stem cell therapies.
SCM is developing stem cell therapies to treat chronic and acute graft-versus-host disease (GvHD), severe atopic dermatitis and severe liver cirrhosis. The company also has a stem cell therapy to treat acute pancreatitis in a Korean Phase I/IIa trial...